Form 4: Intellia Therapeutics EVP, General Counsel James Basta Reports Stock Transactions

James Basta, EVP and General Counsel of Intellia Therapeutics, reports acquisition of restricted stock units and stock options, as well as a sale of shares to cover tax obligations.

Summary

• On March 1, 2024, James Basta, EVP and General Counsel of Intellia Therapeutics, acquired 32,394 shares of common stock through restricted stock units (RSUs) and was granted an option to purchase 46,752 shares.
• On March 4, 2024, Basta sold 2,297 shares of common stock at $32.99 per share.
• The sale was a mandatory 'sell-to-cover' transaction to satisfy tax withholding obligations upon the vesting of RSUs.
• Following these transactions, Basta beneficially owns 81,571 shares of Intellia Therapeutics common stock.
• The stock option granted on March 1, 2024, has an exercise price of $32.66 and vests in installments starting January 1, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing simply reports transactions related to executive compensation and tax obligations. There's no inherent positive or negative signal.

Positives

• The acquisition of RSUs and stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings to gain insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.

Key Dates